Opexa Therapeutics terminates plans for its public offering of stock

Management thinks offering won’t be in best interest of stockholders

By Devika Patel

Knoxville, Tenn., Sept. 16 – Opexa Therapeutics, Inc. said it has cancelled plans for a public offering of common stock. The deal was announced Monday.

Opexa’s management has assessed that current market conditions are not conducive for an offering on terms that would be in the best interest of Opexa stockholders, the company said in a press release.

The Woodlands, Texas-based Opexa develops and commercializes cell therapies to treat autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis and diabetes.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.